Related by context. All words. (Click for frequent words.) 80 hematologic adverse 77 neutropaenia 77 transaminase elevations 77 hematological toxicity 77 laboratory abnormalities 77 leucopenia 77 ALT flares 76 gastrointestinal toxicities 76 nephrotoxicity 75 myelosuppression 75 hematological adverse 75 non hematological toxicities 75 peripheral sensory neuropathy 74 neutropenia dehydration dyspnea 74 DLTs 74 neutropenia thrombocytopenia 74 febrile neutropenia 74 cytopenias 74 lymphopenia 74 TEAEs 74 Toxicities 73 elevated ALT 73 thromboembolic events 73 thrombocytopenia neutropenia 73 hematologic toxicities 73 hypophosphatemia 73 haematologic 73 leukopenia 72 bone marrow suppression 72 corticosteroid therapy 72 histologic subtype 72 Febrile neutropenia 72 ALT elevations 72 hematological toxicities 72 neutropenia febrile neutropenia 72 anemia neutropenia 72 Neutropenia 72 mg kg dose 72 Infusion Reactions Severe 72 aspartate aminotransferase AST 72 FluCAM arm 72 recurrent VTE 72 EXJADE 71 QTc prolongation 71 Hypotension 71 severe neutropenia 71 TMP SMX 71 limiting toxicity 71 lopinavir r arm 71 EDSS scores 71 sensory neuropathy 71 hypomagnesemia 71 aspartate aminotransferase 71 pyrexia mucositis sepsis febrile 71 dose limiting toxicities 71 hepatotoxicity 71 aminotransferases 71 intracranial hemorrhage ICH 71 acute GvHD 71 HbA 1c levels 71 biologic DMARD 71 events AEs 71 hypercalcemia 71 virological failure 71 alanine aminotransferase 71 neutrophil counts 70 Myelosuppression 70 dermatologic toxicities 70 â ‰ ¥ 70 REYATAZ r arm 70 pheochromocytoma 70 mucosal inflammation 70 hypocalcemia 70 haematological toxicity 70 hemorrhagic complications 70 APTIVUS r 70 intravenous bisphosphonates 70 anemia hemoglobin 70 HER2 overexpression 70 receiving VICTRELIS 70 paresthesias 70 rFVIIa 70 daunorubicin 70 NNRTI resistance 69 CIN3 69 relapsed MM 69 HBeAg seroconversion 69 androgen deprivation 69 gastrointestinal toxicity 69 definite stent thrombosis 69 colorectal adenoma 69 Thrombocytopenia 69 HBeAg negative 69 PREZISTA r arm 69 symptomatic VTE 69 tumor necrosis 69 nadolol 69 severe hypersensitivity reactions 69 AST ALT 69 follicular lymphomas 69 prednisone prednisolone 69 flutamide 69 toxicities 69 hepatorenal syndrome 69 cutaneous squamous cell carcinoma 69 neutropenic fever 69 cerebrovascular events 69 extrapyramidal symptoms 69 thrombocytopenia 69 arterial thromboembolic events 69 mg/m2 dose 69 CsA 69 grade cervical intraepithelial 69 β blockers 69 cytogenetic response 69 gastrointestinal perforation 69 acromegalic patients 69 pancytopenia 69 pharmacokinetic interactions 69 mycophenolate mofetil 69 ara C 69 hyperkalemia 69 trimethoprim sulfamethoxazole 69 amenorrhoea 69 hematologic adverse reactions 69 hyperbilirubinemia 69 doxorubicin docetaxel 68 piperacillin tazobactam 68 non hematologic toxicities 68 transaminases 68 Peripheral edema 68 thrombocytopenic 68 neutropenia anemia 68 FOLPI 68 hyperprolactinemia 68 posaconazole 68 nephrotoxic 68 CYP #A# 68 onset diabetes mellitus 68 elevated serum creatinine 68 discontinuations due 68 thromboembolic 68 serum phosphate levels 68 MCyR 68 ertapenem 68 locoregional recurrence 68 doxorubicin cyclophosphamide 68 serum urate levels 68 advanced adenomas 68 myopathy rhabdomyolysis 68 TNF antagonist 68 CR nPR 68 DOXIL 68 pCR 68 pamidronate 68 recurrent venous thromboembolism 68 recurrent glioblastoma multiforme 68 CCyR 68 adrenal insufficiency 68 neutropenia 68 virologic failure 68 mcg BID 68 candidemia 68 Serious adverse reactions 68 serum aminotransferase levels 68 hypoglycemic events 68 conventional DMARDs 68 renal toxicity 68 unfavorable cytogenetics 68 IFN beta 68 moderate renal impairment 68 cytotoxic chemotherapy 68 hepatic enzymes 68 Erythropoietic therapies may 68 vWD 68 Flu Cy 68 biochemical relapse 68 hemorrhagic cystitis 68 morphometric vertebral fractures 68 nonmelanoma skin cancers 68 PASI scores 68 HGPIN 67 postoperative chemotherapy 67 pericardial effusion 67 alanine aminotransferase ALT 67 postoperative morbidity 67 octreotide LAR 67 astrocytomas 67 Postoperative complications 67 CIMZIA ™ 67 chronic GVHD 67 pT3 67 transaminase 67 alpha interferons 67 SGPT 67 graft dysfunction 67 gout flares 67 osteosarcomas 67 adrenal suppression 67 incidence ≥ 67 antiandrogen 67 androgen suppression 67 myalgia arthralgia 67 proctitis 67 isoproterenol 67 glycated hemoglobin levels 67 somatostatin analog 67 seminomas 67 lenalidomide dexamethasone 67 rebleeding 67 LHRH agonists 67 PAOD 67 4mg/kg 67 neurologic deficits 67 subtrochanteric 67 Stent thrombosis 67 MACCE 67 Dasatinib 67 adriamycin 67 idarubicin 67 heavily pretreated 67 dopaminergic therapy 67 coronary stenosis 67 papillary renal cell carcinoma 67 thrombocytopenic patients 67 lymphocytosis 67 sulfasalazine 67 interferon alfa 2b 67 severe exacerbations 67 neurologic complications 67 fatigue diarrhea nausea 67 atrophic gastritis 67 node metastases 67 PREZISTA r 67 hyperammonemia 67 evaluable subjects 67 hypokalemia 67 5-FU/LV 67 plus 5-FU/LV 67 fosamprenavir 67 serum creatinine levels 67 adjunctive placebo 67 renal insufficiency 67 tumor regressions 67 cervical intraepithelial neoplasia 67 virologic response 67 Dose limiting toxicities 67 infusion reactions 67 hypoglycemic episodes 67 NNT = 67 comparator arm 67 ALT elevation 67 ß blockers 67 MADRS score 67 oxycodone CR 67 myeloproliferative diseases 67 tumor lysis syndrome 67 DMARD therapy 67 refractory NSCLC 67 interstitial pneumonia 67 tardive dyskinesia TD 67 primidone 66 serum phosphate 66 cardiac toxicity 66 venous thromboembolic events 66 tolvaptan 66 bezafibrate 66 idraparinux 66 delayed CINV 66 external genital lesions 66 Angioedema 66 TMC# r 66 curative resection 66 Retreatment 66 Adverse events 66 nonhematologic adverse reactions 66 receiving Vectibix monotherapy 66 Hematologic 66 mucocutaneous reactions 66 receiving XGEVA 66 oral allopurinol 66 liver histology 66 macroalbuminuria 66 neutropenic patients 66 adjunctive ABILIFY 66 SUVmax 66 serum ALT 66 chlorambucil 66 CIN2 + 66 CIMZIA TM 66 basal cell carcinoma BCC 66 proliferative diabetic retinopathy 66 interferon IFN 66 hypoglycaemic episodes 66 virological response 66 COPD exacerbation 66 generalized tonic clonic seizures 66 hematopoietic cancers 66 lactic acidosis 66 PSA nadir 66 thromboembolism 66 DMARDS 66 imatinib therapy 66 hepatocellular carcinomas 66 INCB# [003] 66 IL 1ß 66 serum calcium levels 66 elevated bilirubin 66 generalized seizures 66 QT interval prolongation 66 myeloablative 66 nitrofurantoin 66 Non inferiority 66 hypersensitivity reactions 66 corticosteroid dose 66 oxcarbazepine 66 ribavirin therapy 66 β blocker 66 fluvastatin 66 CHOP chemotherapy 66 Fludarabine 66 dose cytarabine 66 HMG CoA reductase inhibitors 66 acute leukemias 66 docetaxel chemotherapy 66 fatigue asthenia 66 platelet reactivity 66 MULTAQ 66 CMV infection 66 Renal impairment 66 perioperative complications 66 lipid lowering agents 66 skeletal metastases 66 invasive ductal 66 biochemical recurrence 66 complete cytogenetic response 66 serum urate 66 invasive candidiasis 66 overt nephropathy 66 mucositis 66 typical antipsychotics 66 elevated creatinine 66 leukemia AML 66 hyperphenylalaninemia HPA due 66 glomerular filtration 66 renal dysfunction 66 ADPKD 66 QTcF 66 proximal DVT 66 platinum refractory 66 AGILECT R 66 variceal hemorrhage 66 fibrinolysis 66 alkylating agent 66 radiochemotherapy 66 Elitek 66 pulmonary exacerbations 66 PRADAXA #mg 66 Hematologic toxicity 66 mTOR inhibitors 66 prolonged QT interval 66 histological subtype 66 clodronate 66 granisetron 66 recurrent DVT 66 serum PTH 66 baseline HbA1c 66 VIIBRYD 66 hematologic abnormalities 66 nonvertebral fractures 66 MGUS 66 HBeAg 66 myocardial reperfusion 66 dysmenorrhoea 66 umol L 66 anagrelide 66 events SAEs 66 hepatic dysfunction 66 serum cortisol 66 paronychial inflammation 66 beta blocker therapy 66 del 5q MDS 66 metastatic GIST 66 thromboembolic complications 66 plus methotrexate 66 anthracycline taxane 66 dysplastic lesions 65 Dermatologic toxicities 65 TNF blocker therapy 65 cytogenetic responses 65 torsade de pointes 65 Ribavirin causes 65 Thal Dex 65 inotropic 65 neutrophil count 65 metformin monotherapy 65 mcg mL 65 CIN2 65 tigecycline 65 elevated LDH 65 follicular lymphoma FL 65 PROMACTA 65 prospectively stratified 65 ecchymosis 65 PegIFN RBV 65 AZT zidovudine Retrovir 65 MALT lymphoma 65 virologic breakthrough 65 GnRH agonist 65 vesicoureteral reflux 65 hepatic failure 65 CrCl 65 amenorrhea 65 surgical debulking 65 bacteriuria 65 Oral corticosteroids 65 RLAI 65 gastroduodenal 65 concomitant medications 65 hypercholesterolaemia 65 hypoperfusion 65 indinavir 65 EBRT 65 hypersensitivity reaction 65 BARACLUDE ® 65 x ULN 65 proteinuria 65 coagulopathy 65 placebo dexamethasone 65 Nilotinib 65 thrombocytosis 65 nucleoside analogs 65 certolizumab 65 prolactin levels 65 erythropoietic 65 achieved ACR# 65 SCr 65 hyperalgesia 65 solifenacin 65 nadroparin 65 virologic failures 65 dexamethasone Decadron 65 paclitaxel cisplatin 65 HER2 expression 65 cisplatin chemotherapy 65 riociguat 65 severe rotavirus gastroenteritis 65 intravascular hemolysis 65 CR CRu 65 Peripheral neuropathy 65 intraventricular hemorrhage 65 tamoxifen Nolvadex ® 65 histologically confirmed 65 salmeterol fluticasone 65 genotypic resistance 65 symptomatic intracranial hemorrhage 65 amphotericin B 65 enalapril 65 endothelin receptor antagonists 65 resectable 65 CLL SLL 65 neurologic sequelae 65 nonfatal MI 65 unstable angina pectoris 65 cerebral vasospasm 65 adverse reactions incidence 65 ZYVOX 65 perioperative mortality 65 recurrent UTI 65 GISTs 65 antiarrhythmic drugs 65 refractory AML 65 partial remissions 65 estramustine 65 intravitreal injections 65 8mg/kg 65 cidofovir 65 cytogenetic abnormalities 65 Doxil ® 65 hemoptysis 65 plasma uric acid 65 VUR 65 esophagitis 65 systemic corticosteroid 65 NAbs 65 ritonavir boosted lopinavir 65 urothelial carcinoma 65 hydroxymethyl coenzyme 65 lymphocyte count 65 BYSTOLIC 65 urate lowering therapy 65 nicardipine 65 angiotensin converting enzyme inhibitors 65 Hepatotoxicity 65 thrombotic events 65 interferon ribavirin 65 K ras mutations 65 liver transaminases 65 caspofungin 65 serum IGF 65 ethambutol 65 calcineurin inhibitor 65 transaminase levels 65 mutated KRAS 65 oral prednisolone 65 micafungin 65 d4T stavudine Zerit 65 conjunctival hyperemia 65 anti leukemic 65 dalteparin 65 ropivacaine 65 peginterferon alfa 65 pyrazinamide 65 haematological 65 blastic phase 65 FOLFIRI 65 varices 65 gastric adenocarcinoma 65 Hurthle cell 65 clomipramine 65 voriconazole 65 #mg/m# [001] 65 endometrial carcinoma 65 hepatocellular 65 vWF 65 pericardial effusions 65 leukocytosis 65 idiopathic thrombocytopenic purpura 65 azacitidine 65 DMARDs 65 Navelbine 65 neovascular 65 pegIFN 65 NRTI 65 hepatic cirrhosis 65 colorectal carcinomas 65 platelet inhibitor 65 p = NS 65 graft occlusion 65 Angiomax monotherapy 65 thrombotic complications 65 non splenectomized 65 neuropsychiatric symptoms 65 5FU 65 insulin detemir 65 splenectomized patients 65 neoplasm 65 rFSH 65 metastatic RCC 65 HBeAg positive 65 myelosuppressive chemotherapy 65 Fludara 65 immunomodulatory therapy 65 danazol 65 sotalol 65 elevated transaminases 65 neurological manifestations 65 steroid dexamethasone 65 INVEGA ® 64 Dermatologic Toxicity Dermatologic toxicities 64 K#N 64 #mmHg [001] 64 unresectable HCC 64 MYCAMINE 64 ximelagatran 64 azacytidine 64 systemic toxicity 64 postoperative complication 64 hemodilution 64 advanced adenoma 64 endophthalmitis 64 generalized edema 64 ocular adverse 64 macrolide antibiotic 64 invasive aspergillosis 64 antiepileptic drugs AEDs 64 metastatic malignant melanoma 64 carotid stenosis 64 dose cohort 64 GH deficiency 64 ritonavir boosted 64 eosinophilia 64 vitamin B# folic acid 64 antiemetics 64 CYT# potent vascular disrupting 64 pulmonary dysfunction 64 levodopa therapy 64 thrombocytopenia anemia 64 complete remissions 64 argatroban 64 dosage regimens 64 inhaled budesonide 64 antiepileptic medications 64 tipranavir r 64 osteoclastic 64 desvenlafaxine succinate 64 symptomatic hypotension 64 nonsevere 64 NPH insulin 64 squamous cell carcinoma SCC 64 CANCIDAS 64 abdominal adiposity 64 chronic periodontitis 64 atrioventricular block 64 teriflunomide 64 ABCB1 64 heavily pretreated patients 64 refractory gout 64 IOP lowering 64 UGT#A# * 64 T2DM 64 generalized epilepsy 64 peritumoral brain edema 64 polymyxin B 64 angioedema 64 baseline LDH 64 enterocolitis 64 interferon alfa 64 cabazitaxel 64 HBeAg positive patients 64 hepatitis C genotype 64 recurrent ischemia 64 non metastatic osteosarcoma 64 endometrial hyperplasia 64 methotrexate therapy 64 normal ULN 64 strong CYP#A# inducers 64 #mg BID [001] 64 anaphylactoid reactions 64 headache abdominal pain 64 bleomycin 64 proliferative retinopathy 64 aminotransferase levels 64 serum sodium 64 mitoxantrone 64 perioperatively 64 systemic corticosteroids 64 lymphadenopathy 64 epistaxis 64 sitaxsentan 64 pleural effusion 64 stage IIIB 64 acneform rash 64 pathologic fractures 64 NATRECOR R 64 imipenem 64 squamous cell histology 64 aminotransferase ALT 64 immunosuppressive agents 64 Subgroup analysis 64 variceal bleeding 64 androgen ablation 64 severe renal impairment 64 antibody titer 64 BENICAR HCT 64 FXIII 64 ketoconazole 64 pimecrolimus cream 64 Dose escalation 64 serous ovarian cancer 64 VAPRISOL 64 EGFRIs 64 urothelial 64 dysuria 64 colorectal carcinoma 64 mg/# h 64 antimuscarinic 64 venlafaxine XR 64 cranial irradiation 64 lactate dehydrogenase 64 Navelbine ® 64 systemic hypotension 64 chloride secretion 64 lung carcinomas 64 leiomyomas 64 decitabine 64 octreotide 64 divalproex sodium 64 serum HBV DNA 64 invasive carcinoma 64 Peg IFN 64 serum testosterone 64 discontinuations 64 femoral shaft fracture 64 intravenous cyclophosphamide 64 fluconazole resistant 64 low dose cytarabine 64 periprocedural 64 ACTEMRA TM 64 chronic urticaria 64 hepatic metastases 64 GnRH agonists 64 completely resected 64 EDSS score 64 deferiprone 64 retrograde ejaculation 64 Telintra 64 μg liter 64 RBC transfusion 64 locoregional 64 bacterial prostatitis 64 cholecystitis 64 LNG IUS 64 thrombolytic agents 64 Thrombotic events 64 depressive symptomatology 64 pyrimethamine 64 susceptible isolates 64 revascularizations 64 reinfarction 64 paragangliomas 64 Scale EDSS score 64 HBeAg negative patients 64 carcinoid tumors 64 elotuzumab 64 subependymal giant cell 64 atypical antipsychotic medications 64 symptomatic aortic stenosis 64 antiandrogens 64 μmol L 64 AEs 64 C1 INH deficiency 64 BEACOPP 64 neutropenic 64 efalizumab 64 nephrotoxic drugs 64 HIV HCV coinfected 64 trastuzumab Herceptin ® 64 nondiabetic patients 64 paraprotein 64 Streptococcus pyogenes 64 adverse cytogenetics 64 postoperative AF 64 gastrointestinal adverse reactions 64 eosinophilic asthma 64 ALT AST 64 salmeterol HFA MDI 64 CTAP# Capsules 64 NNRTIs 64 overlapping toxicities 64 analgesic medications 64 somatostatin analogs 64 intravesical therapy 64 ARB telmisartan 64 oblimersen 64 hyperoxaluria 64 inotropes 64 severe oral mucositis 64 aldosterone antagonist 64 receptor tyrosine kinase inhibitor 64 intraoperative complications 64 serum homocysteine 64 akinesia 64 PRADAXA 64 nasopharyngitis headache 64 cinacalcet 64 hypoxemia 64 Eltrombopag 64 anticholinergics 64 metastatic neuroendocrine tumors 64 Mitoxantrone 64 Follicular Lymphoma 64 #mg dose [002] 64 p# activation 64 oral diclofenac 64 methimazole 64 clinically meaningful reductions 64 cisplatin gemcitabine 64 metastatic malignant 64 malignant neoplasm 64 enzyme elevations 64 myoclonus 64 colorectal liver metastases 64 Venous thromboembolism 64 tumor xenograft models 64 TORISEL 64 direct thrombin inhibitors 64 isoenzyme 64 Severe Primary IGFD 64 lymph node involvement 64 azoospermia 64 Xanafide 64 Hypersensitivity reactions 64 elevated plasma concentrations 64 ELOXATIN 64 LPV r 64 T2 lesions 64 CVD mortality 64 mycophenolic acid 64 Hb A1C 64 myelosuppressive 64 paricalcitol 64 % CI #.#-#.# [007] 64 FluCAM 64 moderately emetogenic 64 inflammatory lesions 64 oral Hycamtin 64 neoplasias 64 dermatologic reactions 64 leukemia APL 64 treatment emergent adverse 64 malignant neoplasms 64 neoplasms 64 fibrosis scarring 64 lactate dehydrogenase LDH 64 NMIBC 64 elevated triglyceride levels 64 d4T 64 intravesical 64 mg BID dose 64 ribavirin RBV 64 cyclophosphamide methotrexate 64 IGFBP 3 64 Adjuvant chemotherapy 64 SRBD 64 log# copies mL 64 nonvertebral fracture 64 hemoglobin Hb 64 agranulocytosis 64 ibandronate 64 experienced hypomagnesemia 64 pegylated interferon alfa 64 histologies 64 CTEPH 64 HSCT 64 adjuvant radiotherapy 64 postoperative mortality 64 LEXIVA r 64 chronic eosinophilic leukemia 64 seminoma 63 elevated lipase 63 SGOT 63 TNFalpha 63 hsCRP levels 63 HPA axis suppression 63 #mg/day [002] 63 Candida infection 63 postoperative infections 63 carcinoids 63 microglial activation 63 stomatitis 63 mcg kg REBETOL 63 radiographic findings 63 ICD shocks 63 severe hypoglycemic 63 dysglycemia 63 BEXXAR Therapeutic Regimen 63 protease inhibitors PIs 63 Gleevec resistant 63 liver enzymes ALT 63 chemoradiotherapy 63 PHPT 63 juvenile idiopathic arthritis JIA 63 superficial bladder cancer 63 artery stenosis 63 neoadjuvant therapy 63 relapsing remitting 63 hypertrophic scars 63 chronic idiopathic thrombocytopenic purpura 63 metastatic lesions 63 HNSCC 63 anterior uveitis 63 necrotizing pancreatitis 63 DFMO 63 Fluid retention 63 TTF Therapy 63 DMARD 63 immunoreactivity 63 nonoperative treatment 63 non squamous NSCLC 63 deep venous thromboses 63 neurologic symptoms 63 pulmonary exacerbation 63 post thrombotic syndrome 63 H2 blockers 63 symptomatic pulmonary embolism 63 microvascular complications 63 nonmetastatic 63 undetectable HBV DNA 63 hallucinations dyskinesia 63 revascularization procedures 63 ECOG PS 63 cytopenia 63 CIMZIA TM certolizumab pegol 63 atherogenic dyslipidemia 63 erlotinib Tarceva ® 63 serum potassium levels 63 Chronic pancreatitis 63 allogeneic stem cell 63 nucleoside analogues 63 preoperative chemotherapy 63 grade gliomas 63 thyrotropin 63 FOLFOX4 63 TNF α 63 IV NSCLC 63 autoantibody positive 63 upper gastrointestinal bleeding 63 oral vancomycin 63 tumor recurrence 63 complement inhibitor eculizumab 63 bisoprolol 63 orchitis 63 #mg/day [001] 63 hepatic adverse 63 retransplantation 63 neurologic outcomes 63 tumor histology 63 PREZISTA rtv 63 potentially hepatotoxic 63 fluoxetine paroxetine 63 μg ml 63 maximal doses 63 gemcitabine carboplatin 63 rizatriptan 63 patients receiving ERBITUX 63 platelet inhibition 63 saline placebo 63 alemtuzumab treated 63 essential thrombocythemia 63 LOVENOX R 63 clinicopathological features 63 serum potassium 63 transgene expression 63 nonmetastatic prostate cancer 63 myeloproliferative neoplasms 63 lichen planus 63 pneumonitis 63 benazepril 63 nerve toxicity neurotoxicity 63 T1DM 63 pyridostigmine 63 ARCALYST ® 63 MGd 63 gemifloxacin 63 GI toxicity 63 calcineurin inhibitors 63 angiographic restenosis 63 lumbar spine BMD 63 ursodeoxycholic acid 63 lymphocyte counts 63 concomitant AEDs 63 GOUT 63 pegylated IFN 63 quinolone 63 hepatic fibrosis 63 vinorelbine 63 astrocytoma 63 posttreatment 63 Cholinesterase Inhibitors 63 hepatic impairment 63 alanine transaminase 63 log# reduction 63 cellularity 63 locoregional disease 63 Hypokalemia 63 acute decompensation 63 serum calcium 63 systolic dysfunction 63 lymphoid blast 63 aminotransferase elevations greater 63 R# #mg BID 63 composite endpoint 63 acute gout flares 63 #Gy 63 taxane chemotherapy 63 mg TID 63 mg BID 63 antithrombotic therapy 63 plasminogen activators 63 grade glioma 63 EGFR HER2 63 intracranial bleeding 63 TAXOTERE ® 63 Decitabine 63 coadministration 63 SSc 63 weekly subcutaneous injections 63 PEGylated anti 63 loop diuretic 63 adefovir 63 MAGE A3 ASCI 63 systemic absorption 63 mitomycin C 63 TT genotype 63 pruritis 63 P = .# 63 neutropenic sepsis 63 endometrial thickness 63 demonstrated antitumor activity 63 azole 63 atazanavir ritonavir 63 malabsorptive 63 intra abdominal abscess 63 thyrotoxicosis 63 pomalidomide 63 thromboprophylaxis 63 anaplastic astrocytomas 63 radioiodine therapy